Continuing Education Opportunities

ClotCare Online Resource does not offer continuing education credit. We do, however, provide information and links to continuing education opportunities that we feel may be of value to our users. We hope you find this list useful. If you know of a continuing education opportunity that you feel may be useful to other ClotCare users, please tell us about it. You may contact us at webmaster@clotcare.org. If you are specifically interested in anticoagulation training programs, check out our Training Programs page.

The University of Illinois at Chicago Office of Continuing Education and Meeting Services-Programs offers a number of continuing education opportunities relating to anticoagulation and antithrombotic therapy. To review current opportunities, go to http://www.pharmacyce.uic.edu/Public/Catalog/

Thrombosis-Consult.com has a Free CME section that lists a number of Thrombosis-related CME opportunities. These listings are located at http://thrombosis.freecme.com/gallcourses.php

ThrombosisClinic.com is a continuing medical education resource for health care professionals emphasizing the latest in emerging approaches in the diagnosis, treatment, and prevention of thrombosis. Visit http://www.ThrombosisClinic.com for more information.

HemostasisCME.org offers a number of continuing education opportunities relating to thrombosis. Visit http://www.hemostasiscme.org/
ActivitiesByTopic.asp?tpc=3&title=Coagulopathy for a list of current programs.

The ASHP has thrombosis-related CE programs and webinars online at www.improvingpatientoutcomes.com.

ASHP Advantage has an educational initiative that includes a number of CE programs. Details are available online at www.stopvte.org/activity.aspx

The heart.org has CE programs online at:
Thrombosis: theheart.org/condition/thrombosis-risk/section/cme-programs.do
Atrial Fibrillation: theheart.org/condition/arrhythmia-ep/section/cme-programs.do

Effectively Managing Oral Anticoagulation: 4 part series presented by Discovery Health featuring Jack E. Ansell, MD, B. Gail Macik, MD and Alan K. Jacobson, MD. discoveryhealthcme.discovery.com/beyond/miniPlayer.html?playerId=1225901422

Improving Outcomes in Oral Anticoagulation Therapy Management: This course is provided by Philips Healthcare. The course objective is to educate nurses about managing patients on warfarin therapy and how patient self testing can improve clinical outcomes and quality of life. inrselftest.com/content/clinicians/ceu.

VTE Prevention & Treatment: A Practical "How To"
This Educational Pamphlet will address methods to assess risk for deep-vein thrombosis (DVT), duration of VTE prophylaxis and treatment, and other important issues relevant to the contemporary treatment of VTE. www.sceptercme.com/ScepterOutcomes/EduPDVT

Additional CE Opportunities

• Thrombosis and Hemostasis Summit of North America

Programs no Longer Offering Credit

• Real World Best Practices for DVT Prophylaxis
• Challenges in Dosing Low Molecular Weight Heparin
• Management of Thromboembolism in Cancer Patients: A Case Presentation and Discussion

Thrombosis and Hemostasis Summit of North America

May 3-5, 2012
Hyatt Regency Chicago, Chicago, IL
www.thsna.org

The Thrombosis and Hemostasis Summit of North America (THSNA) is a comprehensive scientific meeting dedicated to thrombosis and hemostasis issues. This first-ever joint summit is a collaboration of the leading non-profit organizations in both fields. THSNA will provide a focused forum for 1,500 attendees with an interest in bleeding and clotting disorders to network, learn, and share across disciplines and disease states. THSNA will highlight basic science, clinical, and laboratory information that reflects the latest understanding of common hemorrhagic and thrombotic disorders. THSNA will:

• Provide evidence-based content focused on thrombosis and hemostasis
• Present cutting edge research
• Integrate the entire multi-disciplinary team
• Establish a channel for the next generation of clinicians and allied health professionals
• Highlight best practices in clinical management
• Drive multi-disciplinary professional networking opportunities
• Advocate for improved patient care and research funding

For more information, or to register for the conference, please visit www.thsna.org.

Real World Best Practices for DVT Prophylaxis

CME Credit hours: 1.5 AMA PRA Category 1 credits

Release date: July 25, 2006
Available for credit through: July 25, 2007

Program Description

Venous thromboembolism (VTE) is a major cause of morbidity and mortality in the United States. While unfractionated heparin (UFH) has been the standard treatment of VTE for many years, low-molecular-weight-heparins (LMWHs) are now commonly used as a therapeutic alternative. Effective prophylaxis and intervention are essential in minimizing VTE risk and reducing the incidence of life-threatening events. There exists a gap in knowledge for the treatment of VTE with secondary prophylaxis, acute PE, as well as a special consideration for the critically ill (e.g. volume overloaded) or patients with comorbidities (e.g. renal insufficiency). Furthermore, the existing clinical data needs to be discussed and interpreted in order to be applied, as well as a discussion surrounding current issues and controversies in VTE treatment and prophylaxis. This program provides concise and contemporary insight addressing concerns practitioners have regarding the management of patients with VTE.

Target Audience

This activity is intended for healthcare providers who treat DVT.

Educational Objectives

Upon completion of this educational activity participants will be able to:

• Discuss the management of patients with venous thromboembolism: Challenges and Opportunities
• Understand treatment and secondary prophylaxis in VTE
• Discuss treatment options for management of acute PE
• Understand the current issues and controversies in VTE treatment and prophylaxis
• Discuss the new and current treatment options for DVT by examining current data
• Identify special considerations for the medically ill or patients with comorbidities

Faculty

• Paul E. Marik, MD, FCCP, FCCM
• Arthur P. Wheeler, MD, FCCP
• Jamie E. Siegel, MD
• Sandra L. Kane-Gill, PharmD, MSc.

View Program

The program is available online at:
http://www.cmediscovery.com/dvt/index.html

Challenges in Dosing Low Molecular Weight Heparin

CME Credit hours: 1.0

Release date: November 15, 2005
Available for credit through: November 15, 2007

Program Description

Anticoagulants are used in a wide variety of patients, for both therapeutic purposes and as prophylaxis against thromboembolism. The efficacy of these agents has been well established in clinical trials.

Unfractionated heparin can be hard to use, it binds to plasma proteins, and so there is wide variation in its anticoagulant effect. Vigilant monitoring of the PTT is necessary. Heparin-induced thrombocytopenia occurs about 3% of the time and this can be a big problem when it occurs.

Low molecular weight heparins are produced by depolymerization of unfractionated heparin, rendering them smaller and thus more bioavailable. There is less binding to plasma proteins and less inactivation by platelet factor 4. Because of their more predicable effects, routine laboratory monitoring for dose adjustment is usually not required.

There are solid clinical trial data indicating that low molecular weight heparins can be used as an alternative to unfractionated heparins. This program’s intention is NOT to review those data. Instead, this program features a discussion between four experts in critical care medicine. The discussion addresses the challenges in dosing and monitoring patients at the extremes of body weight, patients with renal insufficiency, and critically ill patients with altered plasma volume.

Target Audience

This activity is intended for Cardiologists, Hematologists, Intensivists, Pharmacists and other healthcare professionals who treat patients with LMWH.

Educational Objectives

Upon completion of this activity, participants will be able to:

• Maximize safety and efficacy while reducing harm when dosing LMWH.
• Identify dosing considerations in special populations (i.e. critically ill, obese, renal impaired).
• Have a greater understanding of the pharmaco-economics surrounding LMWH.

Faculty

• Joseph F. Dasta, MSc., FCCM, FCCP
• Steven M. Hollenberg, MD
• Sandra L. Kane-Gill, PharmD., MSc.
• Arthur P. Wheeler, MD

View Program

The program is available online at:
http://www.arcmesa.org/lmwh/default.aspx

Cancer and Thromboembolism

Pharmion Corporation has provided ClotCare Online Resource with a publication written by Joseph A. Caprini, MD, MS, FACS, RVT. This case presentation and discussion is entitled Management of Thromboembolism in Cancer Patients: A Case Presentation and Discussion. If you are interested in receiving CME credit for reviewing this publication, simply complete the questions provided and follow the instructions that accompany them.

You will need Adobe Reader to view this document. You may download a free copy from Adobe's website at http://www.adobe.com/products/acrobat/readstep2.html.

Read Management of Thromboembolism in Cancer Patients: A Case Presentation and Discussion